
## Claims

What is claimed is:

1. A compound of formula (I-A)



**I-A**

or a pharmaceutically acceptable salt thereof, wherein:

L is O, $C(R)_2$, or a single bond;

$X_5$ is N or $CR_5$;

$X_6$ is N or $CR_6$;

$X_7$ is N or $CR_7$;

$X_9$ is N or $CR_9$;

$X_{10}$ is N or $CR_{10}$;

$X_{11}$ is N or $CR_{11}$;

each R is independently H or $C_1$-$C_6$ alkyl;

$R_{2a}$ is H, halo, OH, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ haloalkyl, $C_1$-$C_6$ alkoxy, or $C_1$-$C_6$ haloalkoxy;


$R_{3a}$ is H, halo, OH, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ haloalkyl, $C_1$-$C_6$ alkoxy, or $C_1$-$C_6$ haloalkoxy;

$R_{4a}$ is H, halo, OH, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ haloalkyl, $C_1$-$C_6$ alkoxy, or $C_1$-$C_6$ haloalkoxy;


$R_5$, $R_6$, and $R_7$ are defined as follows:

(i) $R_5$, $R_6$, and $R_7$ are each independently H, halo, CN, OH, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ haloalkyl, $C_1$-$C_6$ alkoxy, $C_1$-$C_6$ haloalkoxy, $C_1$-$C_6$ alkylamino, or -W-$(CH_2)_n$-$R_w$;

(ii) $R_5$ is H, halo, CN, OH, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ haloalkyl, $C_1$-$C_6$ alkoxy, $C_1$-$C_6$ haloalkoxy, $C_1$-$C_6$ alkylamino, or -W-$(CH_2)_n$-$R_w$; and $R_6$ and $R_7$, together with the carbon atoms to which they are attached, form a ring of formula:


; or

(iii) $R_5$ and $R_6$, together with the carbon atoms to which they are attached, form a ring of formula:




; and

$R_7$ is H, halo, CN, OH, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ haloalkyl, $C_1$-$C_6$ alkoxy, $C_1$-$C_6$ haloalkoxy, or -W-$(CH_2)_n$-$R_w$:

$R_8$ is H or -O-$(CH_2)_n$-$R_w$;

$R_9$, $R_{10}$, and $R_{11}$ are each independently H, halo, CN, OH, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ haloalkyl, $C_1$-$C_6$ alkoxy, $C_1$-$C_6$ haloalkoxy, or -W-$(CH_2)_n$-$R_w$;

$R_{12}$ and $R_{13}$ are each independently H, halo, CN, OH, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ haloalkyl, $C_1$-$C_6$ alkoxy, $C_1$-$C_6$ haloalkoxy, or -W-$(CH_2)_n$-$R_w$; or $R_{12}$ and $R_{13}$, together with the carbon atoms to which they are attached, form a ring of formula:



;

$Y_1$, $Y_2$, $Z_1$, and $Z_2$ are each independently O or $C(R_{14})_2$;

each $R_{14}$ is independently H, halo, $C_1$-$C_4$ alkyl, or $C_1$-$C_4$ haloalkyl;

each W is independently O or a single bond;

each $R_w$ is independently 3-6 membered cycloalkyl, phenyl, or 5-6 membered heteroaryl, wherein said 3-6 membered cycloalkyl, phenyl, or 5-6 membered heteroaryl may be unsubstituted or may be substituted with 1-3 substituents selected from a group consisting of halo, $C_1$-$C_6$ alkyl, and $C_1$-$C_6$ haloalkyl; and

*n* is 0 or 1;

wherein when $R_8$ is H, then at least one of $X_5$, $X_6$, and $X_7$ is not N or CH;


wherein when $X_7$ is $CR_7$ and $R_7$ is $C_1$-$C_6$ alkyl, then $R_{2a}$ is not H;

wherein when $R_{4a}$ is halo, then $R_{2a}$ is not H;

wherein no more than one of $X_5$, $X_6$, and $X_7$ is N;

wherein no more than one of $X_9$, $X_{10}$, and $X_{11}$ is N.

2. The compound of claim 1, wherein the compound has formula (I-A-1)



**I-A-1**

or a pharmaceutically acceptable salt thereof, wherein:

L, R, $R_{2a}$, $R_{3a}$, $R_{4a}$, $R_8$, $R_9$, $R_{10}$, and $R_{11}$ are as defined in claim 2;

$R_5$, $R_6$, and $R_7$ are each independently H, halo, CN, OH, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ haloalkyl, $C_1$-$C_6$ alkoxy, $C_1$-$C_6$ haloalkoxy, $C_1$-$C_6$ alkylamino, or -W-$(CH_2)_n$-$R_w$; and

$R_{12}$ and $R_{13}$ are each independently H, halo, CN, OH, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ haloalkyl, $C_1$-$C_6$ alkoxy, $C_1$-$C_6$ haloalkoxy, or -W-$(CH_2)_n$-$R_w$.

3. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein L is O.


4. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein each R is H.

5. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt thereof, wherein $R_{2a}$ is H, halo, OH, $C_1$-$C_6$ alkyl, or $C_1$-$C_6$ alkoxy; $R_{3a}$ is H or halo; and $R_{4a}$ is H or $C_1$-$C_6$ alkyl.

6. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein $R_5$ is H, halo, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ haloalkyl, or $C_1$-$C_6$ alkoxy; $R_6$ is H, halo, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ haloalkyl, $C_1$-$C_6$ alkoxy, $C_1$-$C_6$ haloalkoxy, or -W-$(CH_2)_n$-$R_w$; $R_7$ is H, halo, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ haloalkyl, $C_1$-$C_6$ alkoxy, or -W-$(CH_2)_n$-$R_w$; and $R_8$ is H or $OCH_2Ph$.

7. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt thereof, wherein $R_9$ is H, halo, OH, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ alkoxy, or -W-$(CH_2)_n$-$R_w$; $R_{10}$ is H, halo, OH, or $C_1$-$C_6$ alkoxy; $R_{11}$ is H, halo, $C_1$-$C_6$ alkoxy, or $C_1$-$C_6$ haloalkoxy; $R_{12}$ is H; and $R_{13}$ is H.

8. A compound of formula (I-B)



**I-B**

or a pharmaceutically acceptable salt thereof, wherein:

L is O, $C(R)_2$, or a single bond;

$X_{1a}$ is N or CH;

$X_{2a}$ is N, $N^+$-$O^-$, or $CR_{2a}$;

$X_{3a}$ is N or $CR_{3a}$;

$X_{4a}$ is N or $CR_{4a}$;

$X_5$ is N or $CR_5$;

$X_6$ is N or $CR_6$;

$X_7$ is N or $CR_7$;

$X_9$ is N or $CR_9$;

$X_{10}$ is N or $CR_{10}$;

$X_{11}$ is N or $CR_{11}$;

each R is independently H or $C_1$-$C_6$ alkyl;

$R_{2a}$ is H, halo, OH, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ haloalkyl, $C_1$-$C_6$ alkoxy, or $C_1$-$C_6$ haloalkoxy;


$R_{3a}$ is H, halo, OH, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ haloalkyl, $C_1$-$C_6$ alkoxy, or $C_1$-$C_6$ haloalkoxy;

$R_{4a}$ is H, halo, OH, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ haloalkyl, $C_1$-$C_6$ alkoxy, or $C_1$-$C_6$ haloalkoxy;

$R_5$, $R_6$, and $R_7$ are defined as follows:


(i) $R_5$, $R_6$, and $R_7$ are each independently H, halo, CN, OH, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ haloalkyl, $C_1$-$C_6$ alkoxy, $C_1$-$C_6$ haloalkoxy, $C_1$-$C_6$ alkylamino, or -W-$(CH_2)_n$-$R_w$;

(ii) $R_5$ is H, halo, CN, OH, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ haloalkyl, $C_1$-$C_6$ alkoxy, $C_1$-$C_6$ haloalkoxy, $C_1$-$C_6$ alkylamino, or -W-$(CH_2)_n$-$R_w$; and $R_6$ and $R_7$, together with the carbon atoms to which they are attached, form a ring of formula:



; or

(iii) $R_5$ and $R_6$, together with the carbon atoms to which they are attached, form a ring of formula:




; and

$R_7$ is H, halo, CN, OH, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ haloalkyl, $C_1$-$C_6$ alkoxy, $C_1$-$C_6$ haloalkoxy, or -W-$(CH_2)_n$-$R_w$:

$R_8$ is H or -O-$(CH_2)_n$-$R_w$;

$R_9$, $R_{10}$, and $R_{11}$ are each independently H, halo, CN, OH, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ haloalkyl, $C_1$-$C_6$ alkoxy, $C_1$-$C_6$ haloalkoxy, or -W-$(CH_2)_n$-$R_w$;

$R_{12}$ and $R_{13}$ are each independently H, halo, CN, OH, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ haloalkyl, $C_1$-$C_6$ alkoxy, $C_1$-$C_6$ haloalkoxy, or -W-$(CH_2)_n$-$R_w$; or $R_{12}$ and $R_{13}$, together with the carbon atoms to which they are attached, form a ring of formula:



;

$Y_1$, $Y_2$, $Z_1$, and $Z_2$ are each independently O or $C(R_{14})_2$;

each $R_{14}$ is independently H, halo, $C_1$-$C_4$ alkyl, or $C_1$-$C_4$ haloalkyl;

each W is independently O or a single bond;

each $R_w$ is independently 3-6 membered cycloalkyl, phenyl, or 5-6 membered heteroaryl, wherein said 3-6 membered cycloalkyl, phenyl, or 5-6 membered heteroaryl may be unsubstituted or may be substituted with 1-3 substituents selected from a group consisting of halo, $C_1$-$C_6$ alkyl, and $C_1$-$C_6$ haloalkyl; and

*n* is 0 or 1;


wherein when $R_8$ is H, then at least one of $X_5$, $X_6$, and $X_7$ is not N or CH;

wherein one or two of $X_{1a}$, $X_{2a}$, $X_{3a}$, and $X_{4a}$ is N or $N^+$-$O^-$;

wherein no more than one of $X_5$, $X_6$, and $X_7$ is N;

wherein no more than one of $X_9$, $X_{10}$, and $X_{11}$ is N.

9. The compound of claim 8, wherein the compound has formula (I-B-1)



**I-B-1**

or a pharmaceutically acceptable salt thereof, wherein:

L, R, $R_{2a}$, $R_{3a}$, $R_{4a}$, $R_8$, $R_9$, $R_{10}$, and $R_{11}$ are as defined in claim 36;

$X_{2a}$ is N or $N^+$-$O^-$;

$R_5$, $R_6$, and $R_7$ are each independently H, halo, CN, OH, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ haloalkyl, $C_1$-$C_6$ alkoxy, $C_1$-$C_6$ haloalkoxy, $C_1$-$C_6$ alkylamino, or -W-$(CH_2)_n$-$R_w$; and

$R_{12}$ and $R_{13}$ are each independently H, halo, CN, OH, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ haloalkyl, $C_1$-$C_6$ alkoxy, $C_1$-$C_6$ haloalkoxy, or -W-$(CH_2)_n$-$R_w$.

10. The compound of claim 8 or 9, or a pharmaceutically acceptable salt thereof, wherein L is O.

11. The compound of any one of claims 8-10, or a pharmaceutically acceptable salt thereof, wherein $X_{2a}$ is N.

12. The compound of any one of claims 8-10, or a pharmaceutically acceptable salt thereof, wherein $X_{2a}$ is $N^+$-$O^-$.

13. The compound of any one of claims 8-12, or a pharmaceutically acceptable salt thereof, wherein each R is independently H or $CH_3$.

14. The compound of any one of claims 8-13, or a pharmaceutically acceptable salt thereof, wherein $R_{2a}$ is H or halo.

15. The compound of any one of claims 8-14, or a pharmaceutically acceptable salt thereof, wherein $R_{3a}$ is H or $C_1$-$C_6$ alkyl.

16. The compound of any one of claims 8-15, or a pharmaceutically acceptable salt thereof, wherein $R_{4a}$ is H, halo, or $C_1$-$C_6$ alkyl.

17. The compound of any one of claims 8-16, or a pharmaceutically acceptable salt thereof, wherein $R_5$ is H, halo, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ haloalkyl, $C_1$-$C_6$ alkoxy, or $C_1$-$C_6$ alkylamino.

18. The compound of any one of claims 8-17, or a pharmaceutically acceptable salt thereof, wherein $R_6$ is H, halo, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ haloalkyl, $C_1$-$C_6$ alkoxy, $C_1$-$C_6$ haloalkoxy, or -W-$(CH_2)_n$-$R_w$.

19. The compound of any one of claims 8-18, or a pharmaceutically acceptable salt thereof, wherein $R_7$ is H, halo, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ haloalkyl, $C_1$-$C_6$ alkoxy, $C_1$-$C_6$ haloalkoxy, or -W-$(CH_2)_n$-$R_w$.

20. The compound of any one of claims 8-19, or a pharmaceutically acceptable salt thereof, wherein $R_8$ is H.


21. The compound of any one of claims 8-20, or a pharmaceutically acceptable salt thereof, wherein $R_9$ is H, halo, OH, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ alkoxy, or $C_1$-$C_6$ haloalkoxy.

22. The compound of any one of claims 8-21, or a pharmaceutically acceptable salt thereof, wherein $R_{10}$ is H or halo.

23. The compound of any one of claims 8-22, or a pharmaceutically acceptable salt thereof, wherein $R_{11}$ is halo, $C_1$-$C_6$ alkoxy, or $C_1$-$C_6$ haloalkoxy.

24. The compound of any one of claims 8-23, or a pharmaceutically acceptable salt thereof, wherein $R_{12}$ is H, and $R_{13}$ is H.

25. A compound of formula (II)



II

or a pharmaceutically acceptable salt thereof, wherein:

L is O, $C(R)_2$, or a single bond;

$X_{1b}$ is N or $CR_{1b}$;

$X_{2b}$ is N or $CR_{2b}$;

$X_{3b}$ is N or $CR_{3b}$;

$X_{4b}$ is N or $CR_{4b}$;

$X_5$ is N or $CR_5$;

$X_6$ is N or $CR_6$;

$X_7$ is N or $CR_7$;

$X_9$ is N or $CR_9$;

$X_{10}$ is N or $CR_{10}$;

$X_{11}$ is N or $CR_{11}$;

each R is independently H or $C_1$-$C_6$ alkyl;

$R_{1b}$ is H, halo, OH, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ haloalkyl, $C_1$-$C_6$ alkoxy, or $C_1$-$C_6$ haloalkoxy;

$R_{2b}$ is H, halo, OH, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ haloalkyl, $C_1$-$C_6$ alkoxy, or $C_1$-$C_6$ haloalkoxy;


$R_{3b}$ is H, halo, OH, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ haloalkyl, $C_1$-$C_6$ alkoxy, or $C_1$-$C_6$ haloalkoxy;

$R_{4b}$ is H, halo, OH, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ haloalkyl, $C_1$-$C_6$ alkoxy, or $C_1$-$C_6$ haloalkoxy;

$R_5$, $R_6$, and $R_7$ are defined as follows:


(i) $R_5$, $R_6$, and $R_7$ are each independently H, halo, CN, OH, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ haloalkyl, $C_1$-$C_6$ alkoxy, $C_1$-$C_6$ haloalkoxy, $C_1$-$C_6$ alkylamino, or -W-$(CH_2)_n$-$R_w$;

(ii) $R_5$ is H, halo, CN, OH, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ haloalkyl, $C_1$-$C_6$ alkoxy, $C_1$-$C_6$ haloalkoxy, $C_1$-$C_6$ alkylamino, or -W-$(CH_2)_n$-$R_w$; and $R_6$ and $R_7$, together with the carbon atoms to which they are attached, form a ring of formula:



; or

(iii) $R_5$ and $R_6$, together with the carbon atoms to which they are attached, form a ring of formula:




; and

$R_7$ is H, halo, CN, OH, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ haloalkyl, $C_1$-$C_6$ alkoxy, $C_1$-$C_6$ haloalkoxy, or -W-$(CH_2)_n$-$R_w$:

$R_8$ is H or -O-$(CH_2)_n$-$R_w$;

$R_9$, $R_{10}$, and $R_{11}$ are each independently H, halo, CN, OH, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ haloalkyl, $C_1$-$C_6$ alkoxy, $C_1$-$C_6$ haloalkoxy, or -W-$(CH_2)_n$-$R_w$;

$R_{12}$ and $R_{13}$ are each independently H, halo, CN, OH, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ haloalkyl, $C_1$-$C_6$ alkoxy, $C_1$-$C_6$ haloalkoxy, or -W-$(CH_2)_n$-$R_w$; or $R_{12}$ and $R_{13}$, together with the carbon atoms to which they are attached, form a ring of formula:



;

$Y_1$, $Y_2$, $Z_1$, and $Z_2$ are each independently O or $C(R_{14})_2$;

each $R_{14}$ is independently H, halo, $C_1$-$C_4$ alkyl, or $C_1$-$C_4$ haloalkyl;

each W is independently O or a single bond;

each $R_w$ is independently 3-6 membered cycloalkyl, phenyl, or 5-6 membered heteroaryl, wherein said 3-6 membered cycloalkyl, phenyl, or 5-6 membered heteroaryl may be unsubstituted or may be substituted with 1-3 substituents selected from a group consisting of halo, $C_1$-$C_6$ alkyl, and $C_1$-$C_6$ haloalkyl; and

*n* is 0 or 1;


wherein when $R_8$ is H, then at least one of $X_5$, $X_6$, and $X_7$ is not N or CH;

wherein no more than two of $X_{1b}$, $X_{2b}$, $X_{3b}$, and $X_{4b}$ is N;

wherein no more than one of $X_5$, $X_6$, and $X_7$ is N;

wherein no more than one of $X_9$, $X_{10}$, and $X_{11}$ is N.

26. The compound of claim 25, wherein the compound has formula (II-B-1)



**II-B-1**


or a pharmaceutically acceptable salt thereof, wherein:

L, R, $R_{1b}$, $R_{3b}$, $R_{4b}$, $R_8$, $R_9$, $R_{10}$, and $R_{11}$ are as defined in claim 25;


$R_5$, $R_6$, and $R_7$ are each independently H, halo, CN, OH, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ haloalkyl, $C_1$-$C_6$ alkoxy, $C_1$-$C_6$ haloalkoxy, $C_1$-$C_6$ alkylamino, or -W-$(CH_2)_n$-$R_w$; and

$R_{12}$ and $R_{13}$ are each independently H, halo, CN, OH, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ haloalkyl, $C_1$-$C_6$ alkoxy, $C_1$-$C_6$ haloalkoxy, or -W-$(CH_2)_n$-$R_w$.


27. A compound selected from the group consisting of:




**1**;




**2**;




**3**;




**4**;




**5**;




**6**;




**7**;




**8**;




**9**;




**10**;




**11**;




**12**;




**13**;




**14**;




**15**;




**16**;




**17**;




**18**;




**19**;




**20**;




**21**;




**22**;




**23**;




**24**;




**25**;




**26**;




**27**;




**28**;




**29**;




**30**;




**31**;




**32**;




**33**;




**34**;




**35**;




**36**;




**37**;




**38**;




**39**;




**40**;




**41**;




**42**;




**43**;




**44**;




**45**;




**46**;




**47**;




**48**;




**49**;




**50**;




**51**;




**52**;




**53**;




**54**;




**55**;




**56**;




**57**;




**58**;




**59**;




**60**;




**61**;




**62**;




**63**;




**64**;




**65**;




**66**;




**67**;




**68**;




**69**;




**70**;




**71**;




**72**;




**73**;




**74**;




**75**;




**76**;




**77**;




**78**;




**79**;




**80**;




**81**;




**82**;




**83**;




**84**;




**85**;




**86**;




**87**;




**88**;




**89**;




**90**;




**91**;




**92**;




**93**;




**94**;




**95**;




**96**;




**97**;




**98**;




**99**;




**100**;




**101**;




**102**;




**103**;




**104**;




**105**;




**106**;




**107**;




**108**;




**109**;




**110**;




**111** (*rel*-(S,S));




**112** (*rel*-(R,R));




**113** (*rel*-(S,S));




**114** (*rel*-(R,R));




**115**;




**116**;




**117**;




**118**;




**119**;




**120**;




**121**;




**122**;




**123**;




**124**;




**125**;




**126**;




**127**;




**128**;




**129**;




**130**;




**131**;




**132**;




**133**;




**134**;




**135**;




**136**;




**137**;




**138**;




**139**;




**140**;




**141**;




**142**;




**143**;




**144**;




**145**;




**146**;




**147**;




**148**;




**149**;




**150**;




**151**;




**152**;




**153**;




**154**;




**155**;




**156**;




**157**;




**158**;




**159**;




**160**;




**161**;




**162**;




**163**;




**164**;




**165**;




**166**;




**167**;




**168**;




**169**;




**170**;




**171**;




**172**;




**173**;




**174**;




**175**;




**176**;




**177**;




**178**;




**179**;




**180**;




**181**;




**182**;




**183**;




**184**;




**185**;




**186**;




**187**;




**188**;




**189**;




**190**;




**191**;




**192**;




**193**;




**194**;




**195**;




**196**;




**197**;




**198**;




**199**;




**200**;




**201**;




**202**;




**203**;




**204**;




**205**;




**206**;




**207**;




**208**;




**209**;




**210**;




**211**;




**212**;




**213**;




**214**;




**215**;




**216**;




**217**;




**218**;




**219**;




**220**;




**221**;




**222**;




**223**;




**224**;




**225**;




**226**;




**227**;




**228**;




**229**;




**230**;




**231**;




**232**;




**233**;




**234**;




**235**;




**236**;




**237**;




**238**;




**239**;




**240**;




**241**;




**242**;




**243**;




**244**;




**245**;




**246**;



**247**;




**248**;




**249**;




**250**;




**251**;




**252**;




**253**;



**254**;



**255**;



**256**;



**257**;




**258**;




**259**;




**260**;




**261**;




**262**;




**263**;



**264**;




**265**;




**266**;




**267**;




**268**;




**269**;




**270**;




**271**;





**272**;





**273**;





**274**;





**275**;





**276**;





**277**;



**278**;




**279**;




**280**;




**281**;




**282**;



**283**;




**284**;



**285**;




**286**;



**287**;




**288**;




**289**;




**290**;




**292**;




**293**;




**294**;




**295**;




**296**;



**297**;




**298**;



**299**;




**300**;




**301**;



**302**;




**303**; and




**291**;

or a pharmaceutically acceptable salt thereof.


28. A compound selected from the group consisting of:




**1**;




**2**;




**3**;




**4**;




**5**;




**6**;




**7**;




**8**;




**9**;




**10**;




**11**;




**12**;




**13**;




**14**;




**15**;




**16**;




**17**;




**18**;




**19**;




**20**;




**21**;




**22**;




**23**;



**24**;




**25**; and



**26**;


or a pharmaceutically acceptable salt thereof.

29. The compound of claim 28, wherein the compound is



N-(3-carbamoyl-4-fluoro-phenyl)-2-fluoro-6-[4-(trifluoromethoxy)phenoxy]-3-(trifluoromethyl)benzamide; or a pharmaceutically acceptable salt thereof.


30. The compound of claim 29, wherein the compound is



4-[[2-fluoro-6-[2-methoxy-4-(trifluoromethoxy)phenoxy]-3-(trifluoromethyl)benzoyl]amino]pyridine-2-carboxamide;

or a pharmaceutically acceptable salt thereof.


31. The compound of claim 29, wherein the compound is



4-[[3-chloro-2-fluoro-6-[2-methoxy-4-(trifluoromethoxy)phenoxy]benzoyl]amino]pyridine-2-carboxamide;

or a pharmaceutically acceptable salt thereof.


32. The compound of claim 29, wherein the compound is



4-[[2-fluoro-6-[3-fluoro-2-methoxy-4-(trifluoromethoxy)phenoxy]-3-(trifluoromethyl)benzoyl]amino]pyridine-2-carboxamide;

or a pharmaceutically acceptable salt thereof.

33. The compound of claim 29, wherein the compound is



4-[[6-[2-(difluoromethoxy)-4-(trifluoromethoxy)phenoxy]-2-fluoro-3-(trifluoromethyl)benzoyl]amino]pyridine-2-carboxamide;

or a pharmaceutically acceptable salt thereof.

34. The compound of any one of claims 1-33.

35. A pharmaceutical composition comprising a therapeutically effective amount of the compound of any one of claims 1-33, or a pharmaceutically acceptable salt thereof, or the compound of claim 34 and one or more pharmaceutically acceptable carriers or vehicles.

36. A pharmaceutical composition comprising the compound of any one of claims 1-33, or a pharmaceutically acceptable salt thereof, or the compound of claim 34 and one or more pharmaceutically acceptable carriers or vehicles.

37. Use of a compound of any one of claims 1-33, or a pharmaceutically acceptable salt thereof, or the compound of claim 34, or the pharmaceutical composition of claim 35 or 36 in the manufacture of a medicament for the treatment of chronic pain, gut pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, postsurgical pain, visceral pain, multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence, pathological cough, and/or cardiac arrhythmia in a subject by inhibiting a voltage-gated sodium channel.

38. The use of claim 37, wherein the voltage-gated sodium channel is Nav1.8.

39. Use of an effective amount of the compound of any one of claims 1-33, or a pharmaceutically acceptable salt thereof, or the compound of claim 34, or the pharmaceutical composition of claim 35 or 36 in the manufacture of a medicament for treating or lessening the severity of chronic pain, gut pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, postsurgical pain, visceral pain, multiple

sclerosis, Charcot-Marie-Tooth syndrome, incontinence, pathological cough, and/or cardiac arrhythmia in a subject

40. The use of claim 39, where the use comprises treating or lessening the severity in the subject of neuropathic pain, optionally wherein the neuropathic pain comprises post-herpetic neuralgia, idiopathic small-fiber neuropathy, and/or diabetic neuropathy.

41. The use of claim 39, wherein the use comprises treating or lessening the severity in the subject of musculoskeletal pain, optionally wherein the musculoskeletal pain comprises osteoarthritis pain.

42. The use of claim 39, wherein the use comprises treating or lessening the severity in the subject of acute pain, optionally wherein the acute pain comprises acute post-operative pain.

43. The use of claim 39, wherein the use comprises treating or lessening the severity in the subject of postsurgical pain, optionally wherein the postsurgical pain comprises bunionectomy pain and/or abdominoplasty pain.

44. The use of claim 39, wherein the use comprises treating or lessening the severity in the subject of visceral pain.

45. The use of any one of claims 37-44, wherein said subject is to be treated with one or more additional therapeutic agents which are to be administered concurrently with, prior to, or subsequent to treatment with the medicament.

46. A compound of any one of claims 1-33, or a pharmaceutically acceptable salt thereof, or a compound of claim 34, or a pharmaceutical composition of claim 35 or 36 for use as a medicament.